Quantcast

Oxitec Completes Oversubscribed £6.1 Million ($10.2 Million) Fundraising to Commercialise Pioneering Dengue Mosquito Control Technology

June 23, 2014

OXFORD, England, June 23, 2014 /PRNewswire/ –

Oxitec, a pioneer in the control of insects that spread disease and damage crops,
today announced the completion of a GBP6.1 million ($10.2 million) investment round. The
oversubscribed fundraising was supported by existing shareholders, Oxford Capital
Partners, the University of Oxford and East Hill Management, who were joined by a number
of international private investors from South America, Europe and Asia.

The investment follows the first approval of Oxitec’s novel technology for the control
of dengue mosquitoes, which was granted in April by the Brazilian National Technical
Commission for Biosecurity (CTNBio). The company intends to use the new funds to establish
commercial production facilities to enable the roll out of dengue mosquito control
programmes, initially in Brazil. The funding will also support local recruitment and
training for the programmes, and allow Oxitec to expand its activities into additional
countries impacted by dengue fever.

Oxitec’s pioneering technology produces a unique strain of the dengue mosquito (Aedes
aegypti), which contains specific sterility and marker genes. To control dengue mosquito
populations, Oxitec males are released to mate with wild females in the treated area. Male
Aedes aegypti do not bite, and therefore do not spread the dengue virus. The resulting
offspring inherit the additional genes and die before becoming adults. They also inherit
the marker, which is visible under a specific wave length of light, allowing simple
programme monitoring in the field. A series of trials in Brazil, Malaysia and Grand Cayman
have demonstrated the success of the company’s approach, with successive releases of
Oxitec males significantly reducing the wild dengue mosquito population. Oxitec is
currently conducting similar trials in Panama and plans to undertake approval-scale
studies in the Florida Keys shortly.

“This new investment marks a strategic milestone for Oxitec, as we begin the process
of commercialising our unique approach to controlling dengue mosquitoes following our
first approval in Brazil,” said Hadyn Parry, Chief Executive Officer of Oxitec. “The World
Health Organisation estimates that almost half of the world’s population is now at risk
from dengue, and with no specific treatment or vaccine available, effective techniques for
controlling the mosquitoes that spread this potentially fatal virus are urgently needed.
Oxitec’s mosquitoes represent a novel and safe approach to combating dengue, and we look
forward to working with authorities around the world to make our technology available.”

About dengue

The Aedes aegypti mosquito is the main vector of the dengue virus, which infects an
estimated 390 million people per year worldwide. Infection can result in dengue fever,
with a variety of symptoms, including nausea, acute pain and fever. In more serious cases
it can develop into potentially fatal dengue haemorrhagic fever. The dengue mosquito lives
in and around the home and is difficult to control. Conventional methods have proved
unable to prevent the spread of the disease resulting in an estimated 30 fold increase in
incidence globally in the last 50 years. Currently, there is no specific medication or
vaccine available for dengue. The same mosquito Aedes aegypti is also a vector of yellow
fever and chikungunya.

About Oxitec

Oxitec is a pioneer in controlling insects that spread disease and damage crops. It
was established in 2002 as a spin-out from the University of Oxford. Oxitec’s first
products are for the control of Aedes aegypti, the mosquito species primarily responsible
for transmitting dengue fever, and the Mediterranean fruit fly, one of the world’s most
damaging agricultural pests.

Web: http://www.oxitec.com
Facebook: http://www.facebook.com/oxitec
Twitter: http://www.twitter.com/oxitec

SOURCE Oxitec Ltd


Source: PR Newswire



comments powered by Disqus